Clinical-grade production at the volumes rare diseases need. One process from your first research batch to clinical material — no process transfer, no re-validation cliff.
One process from first batch to clinic: no handover restarts the work.
Validation, animal-study and clinical material usually come from different vendors, each with its own process. An early result may not predict the later batch — and every handover restarts work.
Lysa is developing a pipeline-length cell-free process, so the material you validated early is made the way your clinical material will be.
Tell us the molecule, the volume per year and the stage it is at.